Literature DB >> 26810419

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Peter G Pappas1, Carol A Kauffman2, David R Andes3, Cornelius J Clancy4, Kieren A Marr5, Luis Ostrosky-Zeichner6, Annette C Reboli7, Mindy G Schuster8, Jose A Vazquez9, Thomas J Walsh10, Theoklis E Zaoutis11, Jack D Sobel12.   

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  azoles; candidemia; echinocandins; fungal diagnostics; invasive candidiasis

Mesh：

Year:  2016        PMID： 26810419     DOI： 10.1093/cid/civ1194

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  132 in total

1.  Protective effect of fungal extracellular vesicles against murine candidiasis.

Authors:  Gabriele Vargas; Leandro Honorato; Allan Jefferson Guimarães; Marcio L Rodrigues; Flavia C G Reis; André M Vale; Anjana Ray; Joshua Daniel Nosanchuk; Leonardo Nimrichter
Journal:  Cell Microbiol       Date:  2020-07-22       Impact factor: 3.715

2.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

3.  Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Bo Bo Win Maung; Robert S Mansbach; Michael R Hodges; Malcolm A Finkelman; Karen Joy Shaw; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  The Rim Pathway Mediates Antifungal Tolerance in Candida albicans through Newly Identified Rim101 Transcriptional Targets, Including Hsp90 and Ipt1.

Authors:  Cécile Garnaud; Encar García-Oliver; Yan Wang; Danièle Maubon; Sébastien Bailly; Quentin Despinasse; Morgane Champleboux; Jérôme Govin; Muriel Cornet
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Recommendations for intra-abdominal infections consensus report.

Authors:  Vildan Avkan-Oğuz; Nurcan Baykam; Selman Sökmen; Rahmet Güner; Fatih Agalar; Emine Alp; Ahmet Doğrul; Özge Turhan; Canan Ağalar; Behice Kurtaran; İbrahim Ethem Geçim; Reşat Özaras; Gürdal Yılmaz; Ayhan Akbulut; İftihar Koksal
Journal:  Ulus Cerrahi Derg       Date:  2016-12-01

Review 6.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

7.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

8.  Response to Kato et al.: Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection.

Authors:  H Russell Day; Mark P Breazzano; Karen C Bloch; Edward F Cherney; Sean P Donahue; John B Bond
Journal:  Infection       Date:  2019-03-11       Impact factor: 3.553

9.  ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait.

Authors:  Suhail Ahmad; Leena Joseph; Josie E Parker; Mohammad Asadzadeh; Steven L Kelly; Jacques F Meis; Ziauddin Khan
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Authors:  Sébastien Bailly; Elodie Gautier-Veyret; Minh P Lê; Lila Bouadma; Olivier Andremont; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Magalhaes; Jordane Lebut; Aguila Radjou; Roland Smonig; Michel Wolff; Laurent Massias; Claire Dupuis; Jean-François Timsit
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.